Waheed Nadia 4

What Happened Nadia Waheed, Chief Medical Officer of Ocular Therapeutix (OCUL), disposed of 7,863 shares on 2026-02-12 in an open-market sale. The weighted-average price was $9.04 per share, producing gross proceeds of roughly $71,082. The sale was a sell-to-cover tied to the vesting of restricted stock units (RSUs) and was executed under a pre-established automatic instruction rather than as a discretionary trade.

Key Details

• Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (filed late relative to the 2-business-day rule).
• Shares sold: 7,863; weighted-average price: $9.04; proceeds ≈ $71,082.
• Price range: $8.9950 to $9.0840 across multiple executions (report lists weighted average; reporter will provide per-price breakdown upon request).
• Reason/footnote: Sell-to-cover to satisfy tax withholding for RSUs that vested on February 11, 2026; implemented via a durable automatic sale instruction adopted June 1, 2024 (not a discretionary trade).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.

Context Sell-to-cover transactions to satisfy tax withholding on vested RSUs are common and typically considered routine administrative sales rather than a statement of confidence or lack thereof. The late filing reduces immediate disclosure transparency and may be noted by investors, but the footnotes indicate this was an automatic, non-discretionary tax withholding sale.